Objective: Bladder carcinoma is one of the most common tumors in the world and, despite the therapy currently available, most of the patients relapse. MicroRNA- 100 is down regulated in bladder cancer tissue in comparison to normal tissue; however, clinical significance of miR-100 in human bladder cancer has not been elucidated. The aim of study was to correlate miR 100 expression levels with tumor grade, stage and recurrence.
Methods: Expression of miR-100 in 26 pairs of bladder cancer and adjacent normal tissues were analysed by Sybergreen RT-PCR. The expression levels of miR 100 in tumor and normal were normalised with 18s gene. The expression levels of miR 100 expression were analysed in fold change (DDCT method). The difference between groups were analysed by student t test and Anova.
Results: Downregulation of miR-100 expression in tumor was an important finding in our study. MiR-100 expression were decreased (n=24) in tumour tissue in comparison with normal bladder urothelium. Mean expression of miR-100(fold change) was 0.33 ± 0.35 and significantly decreased on comparison to normal (p=0.001). There is no correlation of miR-100 expression levels with gender and age (p=0.583). Mean expression of miR-100 in low grade was 0.41 ± 0.38 whereas in high grade 0.22 ± 0.26 (p=0.182). Ta tumors had mean (fold change) 0.42 ± 0.39, T1 had mean value of 0.25 ± 0.30 and T 2 had mean value of 0.24 ± 0.30.(p=0.463) miR-100 expression levels were decreased in MIBC(T2) more than NMIBC (Ta,T1) (p=0.473).Mean levels 2^-DDCT (fold change) in recurrent tumors were 0.16 ± 0.19 whereas fold change in nonrecurring tumors was 0.40 ± 0.38.(p=0.045) 1 patient with T2 tumor underwent progression with all patients surviving till end of study.
Conclusions: miR-100 expression is down regulated in Bladder cancer tissue than normal bladder urothelium. The miR-100 expression levels were decreased in all bladder tumors however reaching significance in recurrent bladder tumor, suggesting use of miR 100 as potential marker for further risk stratification and prognosis in treatment of urinary bladder cancer.
Published Date: 2020-06-18; Received Date: 2020-01-05